Format

Send to

Choose Destination
Trends Mol Med. 2010 Apr;16(4):171-83. doi: 10.1016/j.molmed.2010.01.006. Epub 2010 Mar 19.

Proteomic approaches in the search for biomarkers of liver fibrosis.

Author information

1
Centre for Infection, Division of Cellular and Molecular Medicine, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. mcowan@sgul.ac.uk <mcowan@sgul.ac.uk>

Abstract

Chronic liver diseases (CLDs) can cause progressive hepatic fibrosis culminating in cirrhosis. Fibrosis staging requires liver biopsy, which is invasive, expensive and frequently poorly tolerated by patients. Serum-based panels of fibrosis biomarkers have been developed as alternatives to biopsy. Recent advances in high-throughput proteomic methods have the potential to optimise combinations of biomarkers for the diagnosis of liver fibrosis. Here, we review the key recent developments in the field of proteomics and their application to this important clinical question. We critically discuss the challenges and priorities for future research that are of critical importance to clinical hepatology.

PMID:
20304704
DOI:
10.1016/j.molmed.2010.01.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center